CareDx, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CareDx, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $12.50M | Mar 22, 2018 |
| FY2017 | Sep 30, 2017 | $12.19M | Mar 22, 2018 |
| FY2017 | Jun 30, 2017 | $12.05M | Mar 22, 2018 |
| FY2017 | Mar 31, 2017 | $11.58M | Mar 22, 2018 |
| FY2017 | Dec 31, 2016 | $10.86M | Mar 22, 2018 |
| FY2017 | Sep 30, 2016 | $12.48M | Mar 22, 2018 |
| FY2017 | Jun 30, 2016 | $10.74M | Mar 22, 2018 |
| FY2017 | Mar 31, 2016 | $6.56M | Mar 22, 2018 |
| FY2016 | Dec 31, 2015 | $6.65M | Apr 21, 2017 |
| FY2016 | Sep 30, 2015 | $7.15M | Apr 21, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $379.81M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $333.79M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $280.32M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $321.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $296.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $192.19M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $35.82M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $33.81M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $31.45M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $25.98M | Feb 28, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $81.61M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $43.58M | Feb 28, 2020 |
| FY2019 | Dec 31, 2017 | $26.95M | Feb 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.35M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $52.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($190.28M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($76.61M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($30.66M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($18.71M) | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | ($4.78M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | ($1.81M) | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($7.85M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($7.53M) | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.78M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $40.77M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($203.36M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($77.23M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($29.73M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($22.53M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($24.53M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($15.58M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($20.29M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($37.33M) | Mar 6, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $72.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $82.42M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $90.39M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $76.53M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $48.94M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $30.71M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $14.51M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $12.39M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $12.39M | Mar 6, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.03M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $38.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($18.39M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($25.24M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($19.29M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $33.43M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($2.77M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($4.01M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($14.31M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($16.52M) | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $2.04M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $186.0K | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $549.0K | Mar 6, 2019 |
| FY2017 | Dec 31, 2015 | $1.20M | Mar 22, 2018 |
| FY2016 | Dec 31, 2014 | $733.0K | Apr 21, 2017 |
| FY2015 | Dec 31, 2013 | $98.0K | Mar 29, 2016 |
| FY2014 | Dec 31, 2012 | $141.0K | Mar 31, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $413.23M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $491.05M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $466.83M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $542.99M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $566.62M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $368.51M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $151.74M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $130.70M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $83.57M | Mar 6, 2019 |
| FY2017 | Sep 30, 2017 | $75.09M | Mar 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.13M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $112.62M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $205.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $112.08M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $100.75M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $90.83M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $52.74M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $34.77M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $89.52M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $56.97M | Mar 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $303.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $378.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $261.33M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $430.91M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $465.88M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $277.68M | Feb 28, 2024 |
| FY2020 | Dec 31, 2019 | $99.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $95.93M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($6.13M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $19.48M | Mar 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.34M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $40.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $40.34M | Feb 28, 2025 |
| FY2024 | Dec 31, 2022 | $37.52M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $36.98M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $23.86M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $23.86M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $12.01M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $12.01M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $13.84M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($735.36M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($626.24M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($678.27M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($460.44M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($383.19M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($352.53M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($333.81M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($311.85M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($268.02M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($212.55M) | Mar 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $114.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $82.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $89.92M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $348.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $134.67M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $38.22M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $64.62M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $16.90M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $17.26M | Mar 6, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $34.06M | Mar 22, 2018 |
| FY2016 | Dec 31, 2016 | $23.94M | Apr 21, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 54.77M | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | 51.50M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | 53.53M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 52.92M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 49.44M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 42.50M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 41.38M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 28.83M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 21.28M | Mar 22, 2018 |